Not for injection or human administration
Animal and cell research points to several overlapping pathways: VEGFR2 upregulation: BPC-157 has been shown in rat tendon fibroblast studies to upregulate VEGFR2 (vascular endothelial growth factor receptor 2) expression, promoting angiogenesis
Further, we can assume that the neuromuscular junction function is a needed precondition that BPC 157 therapy (effective in rat injury, given intraperitoneally or in drinking water or topically, at the site of injury) induces the healing of the transected muscle [71], crushed muscle [72], denervated muscle [73], and myotendinous junction [74]
Using a sensitive analytical technique called mass spectrometry, they tracked the peptide as it was broken down by enzymes naturally present in the blood, and identified all the fragments that were produced
We also take a hands-on approach to dosing, working with you closely to tailor each treatment to your bodys unique needs and wellness goals
If BPC-157 becomes available through a compliant pathway, Maximus is preparing to offer it with structure around it
